Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

2960 - A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer

Date

09 Sep 2017

Session

Breast cancer, early stage

Presenters

Philip Lammers

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

P.E. Lammers1, M. Dank2, R. Masetti3, R. Abbas4, F. Hilton5, J. Coiro6, I. Jacobs7

Author affiliations

  • 1 Division Of Hematology/oncology, Department Of Internal Medicine, Meharry Medical College, 37208-3501 - Nashville/US
  • 2 Cancer Center, Semmelweis University, Budapest/HU
  • 3 Multidisciplinary Breast Center, Catholic University of Rome, Rome/IT
  • 4 Clinical Pharmacology, Pfizer Inc, 19426 - Collegeville/US
  • 5 Pfizer Essential Health Clinical Statistics, Pfizer Inc, 06340 - Groton/US
  • 6 Global Biosimilars Medical Affairs, Pfizer Inc, New York/US
  • 7 Oncology Biosimilars, Pfizer Inc, New York/US
More

Resources

Abstract 2960

Background

This comparative clinical trial evaluated efficacy, safety, immunogenicity and pharmacokinetics (PK) of PF-05280014, a potential trastuzumab biosimilar, vs trastuzumab sourced from the EU (trastuzumab-EU), both given with D and C, as neoadjuvant treatment for operable HER2+ breast cancer.

Methods

Patients (pts; N = 226) were stratified by primary tumor size and hormone receptor status and randomized 1:1 to receive PF-05280014 or trastuzumab-EU (8 mg/kg at Cycle 1; 6 mg/kg thereafter), both with D (75 mg/m2) and C (target AUC 6), every 3 wks for 6 treatment cycles. The study was powered to test whether PF-05280014 was noninferior to trastuzumab-EU in the percentage of pts with Cycle 5 Ctrough (pre-dose Cycle 6) >20 μg/mL. Efficacy was measured by the percentage of pts with pathological complete response (pCR), defined as the absence of invasive neoplastic cells in breast and lymph nodes after neoadjuvant therapy, and objective response rate (ORR). Safety and immunogenicity were also assessed.

Results

The percentage of pts with Cycle 5 Ctrough >20 μg/mL was 92.1% for PF-05280014 and 93.3% for trastuzumab-EU; the lower limit of the 95% CI (-8.02% to 6.49%) for the stratified difference between groups was above the noninferiority margin (-12.5%). The pCR rate was 47.0% (95% CI: 36.9-57.2) for PF-05280014 and 50.0% (95% CI: 39.0-61.0) for trastuzumab-EU. Central radiology review-assessed ORR was 88.1% (95% CI: 80.2-93.7) for PF-05280014 and 82.0% (95% CI: 72.5-89.4) for trastuzumab-EU. All causality, grade 3-4 treatment-emergent adverse events were reported by 38.1% (PF-05280014) vs 45.5% (trastuzumab-EU) of pts. No pts in the PF-05280014 and 1 (0.89%) in the trastuzumab-EU group had positive anti-drug antibody titer.

Conclusions

PF-05280014 demonstrated similarity in efficacy, safety and immunogenicity, and noninferiority in PK to trastuzumab-EU. A separate comparative safety and efficacy study (NCT01989676) is evaluating PF-05280014 vs trastuzumab-EU, both given with paclitaxel, as first-line treatment for HER2+ metastatic breast cancer.

Clinical trial identification

NCT02187744; EudraCT No: 2013-004679-11

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Disclosure

P.E. Lammers: Advisory boards with Pfizer Inc. M. Dank: Member of Biosimilars Oncology European Advisory Board with Pfizer Inc since 2013. R. Abbas, F. Hilton, J. Coiro, I. Jacobs: Full time employee and lares stock holdings and/or stock options from Pfizer Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.